Cat. No.: DAB-0012072
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG2a |
| Host Species | Mouse |
| Reactivity | Human |
| Applications | IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the C terminal of Glut1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SLC2A1 |
| UniProt No. | P11166 |
| Gene ID | 6513 |
| Gene Description | Glucose transporter 1 is a widely expressed transport protein that displays a broad range of substrate specificity in transporting a number of different aldose sugars as well as an oxidized form of vitamin C into cells. Glut1 is responsible for the basal-level uptake of glucose from the blood through facilitated diffusion. Research studies show that Glut1 and the transcription factor HIF-1α mediate the regulation of glycolysis by O-GlcNAcylation in cancer cells. Additional studies demonstrate that Glut1 is required for CD4 T cell activation and is critical for the expansion and survival of T effector cells. Mutations in the corresponding SLC2A1 gene cause GLUT1 deficiency syndromes, a pair of neurologic disorders characterized by delayed development, seizures, spasticity, paroxysmal exercise-induced dyskinesia, and acquired microcephaly. Two other neurologic disorders - dystonia-9 and susceptibility to idiopathic generalized epilepsy 12 - are also caused by mutations in the SLC2A1 gene. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Stored at 4 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in a Tris-based buffer with 1% BSA and less than 0.1% sodium azide. Stable for 24 months when |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
